IL13R alpha 2 CAR-T by TCR Cure Biopharma Technology for Glioma: Likelihood of Approval

IL13R alpha 2 CAR-T is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Glioma.

Freeline touts positive data for Gaucher disease therapy – Pharmaceutical Technology

Freeline’s gene therapy FLT201 introduces a transgene to produce an engineered GCase variant, the enzyme responsible for the symptoms of Gaucher disease. Credit: dizain via

May 10, 2024

Biotest and SteinCares partner to improve access to plasma-derived products in Latin America – Biotech Investments

EQS-News: Biotest AG / Key word(s): Agreement Biotest and SteinCares partner to improve access to plasma-derived products in Latin America 29.10.2024 / 09:00 CET/CEST The

October 30, 2024

Virtual physical therapy programs can be just as good as in-person care, report says

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Many virtual programs … Sign up to

June 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.